TP04HN106
Phase 2Small molecule
TP04HN106 is one of 40 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Amyotrophic Lateral Sclerosis
#DrugCompanyPhaseTrials
1Vimpat
UCBApproved
Enablex
AbbVieApproved
Nourianz
Kyowa Kirin Co., Ltd.Approved
Bosulif
PPrism Pharmaceuticals
Approved
Qalsody
BiogenApproved
Quinidine Gluconate
WWyeth-Lederle Vaccines
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Transderm Scop
BBaxter Healthcare Corporation
Approved
Mirapex
Boehringer IngelheimApproved
Avodart
Akero TherapeuticsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Amyotrophic Lateral Sclerosis1 trial
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
Recruiting·TTalengen Institute of Life Sciences, Shenzhen, P.R. China.·Phase 1/2·NCT06726577·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TP04HN106. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details